Drug Search Results
More Filters [+]

DNL-151

Alternative Names: dnl-151, dnl 151, dnl151
Latest Update: 2025-01-13
Latest Update Note: News Article

Product Description

DNL151 is an orally available, brain-penetrant inhibitor of the leucine-rich repeat kinase 2 (LRRK2). It started out as a backup to Denali’s lead LRRK2 inhibitor, DNL201; but it is now is its lead candidate after development of DNL201 was stopped in 2020. (Sourced from: https://www.alzforum.org/therapeutics/dnl151)

Mechanisms of Action: LRRK2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: Denali Therapeutics

Clinical Description

Map of Global Clinical Trials for DNL-151

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LRRK2-PD

P2

Recruiting

Parkinson's Disease

2026-04-30

Recent News Events